IRVINE, Calif., July 26,
2017 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW),
the global leader in patient-focused innovations for structural
heart disease and critical care monitoring, today reported
financial results for the quarter ended June 30,
2017.
Second Quarter and Recent Highlights:
- Sales grew 11 percent to $842
million; underlying1 sales increased 15 percent
to $864 million
- Global THVT sales grew 16 percent to $488 million; underlying sales increased 23
percent
- U.S. THVT sales grew 28 percent to $316
million
- EPS was $0.86, an increase of 48
percent; adjusted2 EPS grew 42 percent to $1.08
- 2017 adjusted EPS guidance increased to $3.65 to $3.85, from $3.43 to $3.55
- Recent FDA approvals of SAPIEN 3 valve-in-valve, INSPIRIS
RESILIA and HemoSphere
"We are pleased to report another quarter of strong performance,
which continued the trend of robust growth driven by long term
investments in innovative therapies," said Michael A. Mussallem, chairman and CEO.
"Strong demand for TAVR therapy resulted in total sales growth of
15 percent on an underlying basis, which also reflected strength in
all three of our product lines across all regions. And our
transcatheter mitral and tricuspid valve technologies continue to
represent exciting opportunities for breakthrough therapies for
patients in need."
Second Quarter 2017 Results
Sales for the quarter ended June 30, 2017 were $841.8 million, up 10.9 percent. Including the
consumption of $22.5 million of
stocking inventory in Germany, on
an underlying basis sales grew 15.3 percent over the second
quarter last year. Net income for the quarter ended
June 30, 2017 was $186.1
million, or $0.86 per
share. Adjusted earnings per share grew 42.1 percent to
$1.08. Both reported and
adjusted earnings per share include a $0.13 favorable impact from the company's excess
tax benefit related to employee stock-based compensation compared
to last year.
For the quarter, the company reported Transcatheter Heart Valve
Therapy (THVT) sales of $487.5
million, a 16.5 percent growth rate over the second quarter
last year, or 23.3 percent on an underlying basis. Growth was led
by continued strong therapy adoption across all
geographies.
As a reminder, in the first quarter customers in Germany purchased a net $61.8 million of SAPIEN 3 valves as
additional inventory in anticipation of a potential supply
interruption resulting from intellectual property litigation in
that country. The company included these stocking sales in
its reported results, but excluded them from the adjusted results
reported in the first quarter, and will add them back to the
adjusted results in subsequent quarters as this inventory is
consumed to better reflect actual hospital usage.
In the U.S., THVT sales for the quarter were $316.3 million, a 28.4 percent growth rate over
the second quarter last year. "Therapy adoption continued to
be strong, and our SAPIEN 3 valve has sustained its excellent
clinical performance across large and small valve centers," said
Mussallem.
Surgical Heart Valve Therapy sales for the quarter were
$207.1 million, up 4.2 percent
compared to the second quarter last year, or up 5.7 percent on an
underlying basis. This growth benefitted from the recovery of
the 2016 mitral valve supply interruption that lowered sales last
year. Also lifting growth was continued strong demand of the
EDWARDS INTUITY Elite valve system, which more than offset a shift
of surgical aortic valve procedures to TAVR in the U.S.
Critical Care sales were $147.2
million for the quarter, representing an increase of 3.7
percent versus last year, or 5.1 percent on an underlying
basis. Strong performance was driven by double-digit growth
in the company's Enhanced Surgical Recovery program, particularly
in the U.S. and Asia Pacific.
For the quarter, the company's gross profit margin was 74.9
percent, compared to 73.3 percent in the same period last year.
This increase was driven primarily by a more profitable product
mix, led by growing sales of transcatheter valves.
Selling, general and administrative expenses increased to
$243.8 million for the quarter,
compared to $228.8 million in the
prior year quarter. This increase was driven primarily by sales and
marketing expenses related to transcatheter valves.
Research and development investments for the second quarter
increased to $134.4 million, compared
to $112.5 million in the prior year
period. This increase was primarily the result of continued
investments in transcatheter valve development programs.
Cash flow from operating activities for the second quarter was
$197.7 million. After capital
spending of $58.0 million, free cash
flow was $139.7 million.
Cash, cash equivalents and short-term investments totaled
$1.13 billion at June 30,
2017. Total debt was $1.02
billion.
During the second quarter, the company repurchased 0.8 million
shares for $73.8 million.
Average diluted shares outstanding during the quarter were 215.7
million.
Outlook
For the full year 2017, given the strong first half results, the
company's full year sales estimate is now at the high end of its
previous $3.2 to $3.4 billion
guidance. The company is also raising its estimate for 2017
adjusted earnings per share to $3.65 to
$3.85, from $3.43 to
$3.55.
For the third quarter of 2017, the company projects underlying
sales, adjusting for the impact of Germany stocking sales consumption, to be
between $810 and $850 million, and
adjusted earnings per share of $0.80 to
$0.90.
"As we reflect on our first half results, we are very pleased
with the performance achieved across all of our product lines and
believe our future remains bright," said Mussallem. "We are
confident our valuable innovations will result in a continued
strong outlook as we deliver important solutions for the patients
we serve."
About Edwards
Lifesciences
Edwards Lifesciences, based in Irvine,
Calif., is the global leader in patient-focused medical
innovations for structural heart disease, as well as critical care
and surgical monitoring. Driven by a passion to help patients, the
company collaborates with the world's leading clinicians and
researchers to address unmet healthcare needs, working to improve
patient outcomes and enhance lives. For more information, visit
www.Edwards.com and follow us on Twitter @EdwardsLifesci.
Conference Call and Webcast
Information
Edwards Lifesciences will be hosting a conference call today at
2:00 p.m. PT to discuss its second quarter results. To
participate in the conference call, dial (877) 704-2848 or (201)
389-0893. For 72 hours following the call, an audio replay
can be accessed by dialing (877) 660-6853 or (201) 612-7415 and
using conference number 13665308. The call will also be
available via live or archived webcast on the "Investor Relations"
section of the Edwards web site at ir.edwards.com or
www.edwards.com. A live stream and archived replay can also be
accessed via mobile devices by downloading Edwards' IR App for
iPhone and iPad or Android.
This news release includes forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934. These
forward-looking statements can sometimes be identified by the use
of words such as "may," "will," "should," "anticipate," "believe,"
"plan," "project," "estimate," "expect," "intend," "guidance,"
"outlook," "optimistic," "aspire," "confident" or other forms
of these words or similar expressions and include, but are not
limited to, statements made by Mr. Mussallem, third quarter and
full year 2017 financial guidance, and information in the Outlook
section. Forward-looking statements are based on estimates
and assumptions made by management of the company and are believed
to be reasonable, though they are inherently uncertain and
difficult to predict. Our forward-looking statements speak
only as of the date on which they are made and we do not undertake
any obligation to update any forward-looking statement to reflect
events or circumstances after the date of the statement. If
the company does update or correct one or more of these statements,
investors and others should not conclude that the company will make
additional updates or corrections.
Forward-looking statements involve risks and uncertainties that
could cause actual results or experience to differ materially from
that expressed or implied by the forward-looking statements.
Factors that could cause actual results or experience to differ
materially from that expressed or implied by the forward-looking
statements include uncertainties associated with the effectiveness
and timing of new product launches, competitive dynamics and
therapy adoption, particularly for THVT; the timing and scope of
regulatory approvals and reimbursement levels for our products; the
company's success in developing new products and avoiding
manufacturing and quality issues; the impact of currency exchange
rates; the timing or results of research and development, pending
or future clinical milestones and clinical trials; unanticipated
actions by the U.S. Food and Drug Administration and other
regulatory agencies; unexpected litigation impacts or expenses,
particularly in our THVT patent litigation; and other risks
detailed in the company's filings with the Securities and Exchange
Commission, including its Annual Report on Form 10-K for the year
ended December 31, 2016. These filings, along with important
safety information about our products, may be found at
edwards.com.
Edwards, Edwards Lifesciences, the stylized E logo, EDWARDS
INTUITY, EDWARDS INTUITY Elite, Edwards SAPIEN, Edwards SAPIEN 3,
Enhanced Surgical Recovery program, HemoSphere, INSPIRIS, INSPIRIS
RESILIA, RESILIA, SAPIEN, SAPIEN 3, and Valtech Cardio are
trademarks of Edwards Lifesciences Corporation. All other
trademarks are the property of their respective owners.
|
|
|
|
[1]
|
"Underlying" amounts
are non-GAAP items and in this press release exclude foreign
exchange fluctuations, sales return reserves associated with THVT
product upgrades, and impacts of THVT stocking sales and
consumption in Germany. See the Non-GAAP Financial Information page
and reconciliation tables below.
|
[2]
|
Adjusted earnings per
share is a non-GAAP item computed on a diluted basis and in this
press release excludes impairment of long-lived assets,
intellectual property litigation expenses, amortization of
intellectual property, fair value adjustments to contingent
consideration liabilities arising from acquisitions, and the impact
of THVT stocking sales and consumption in Germany. See the
Non-GAAP Financial Information page and reconciliation tables
below.
|
EDWARDS
LIFESCIENCES CORPORATION
|
Unaudited
Consolidated Statements of Operations
|
(in millions, except per share data)
|
|
|
Three Months
Ended June
30,
|
|
Six Months
Ended June
30,
|
|
2017
|
|
2016
|
|
2017
|
|
2016
|
Net sales
|
$
|
841.8
|
|
|
$
|
759.3
|
|
|
$
|
1,725.3
|
|
|
$
|
1,456.6
|
|
Cost of
sales
|
211.1
|
|
|
202.5
|
|
|
426.7
|
|
|
382.8
|
|
|
|
|
|
|
|
|
|
Gross
profit
|
630.7
|
|
|
556.8
|
|
|
1,298.6
|
|
|
1,073.8
|
|
|
|
|
|
|
|
|
|
Selling, general, and
administrative expenses
|
243.8
|
|
|
228.8
|
|
|
473.4
|
|
|
441.5
|
|
Research and
development expenses
|
134.4
|
|
|
112.5
|
|
|
263.1
|
|
|
214.3
|
|
Intellectual property
litigation expenses
|
7.7
|
|
|
9.1
|
|
|
17.9
|
|
|
21.3
|
|
Change in fair value
of contingent consideration liabilities
|
3.1
|
|
|
0.4
|
|
|
4.2
|
|
|
1.0
|
|
Special
charges
|
31.2
|
|
|
34.5
|
|
|
31.2
|
|
|
34.5
|
|
Interest expense,
net
|
1.4
|
|
|
2.4
|
|
|
3.8
|
|
|
4.8
|
|
Other expense,
net
|
3.5
|
|
|
0.1
|
|
|
5.8
|
|
|
4.1
|
|
|
|
|
|
|
|
|
|
Income before
provision for income taxes
|
205.6
|
|
|
169.0
|
|
|
499.2
|
|
|
352.3
|
|
|
|
|
|
|
|
|
|
Provision for income
taxes
|
19.5
|
|
|
42.4
|
|
|
82.9
|
|
|
82.7
|
|
|
|
|
|
|
|
|
|
Net income
|
$
|
186.1
|
|
|
$
|
126.6
|
|
|
$
|
416.3
|
|
|
$
|
269.6
|
|
|
|
|
|
|
|
|
|
Earnings per
share:
|
|
|
|
|
|
|
|
Basic
|
$
|
0.88
|
|
|
$
|
0.60
|
|
|
$
|
1.97
|
|
|
$
|
1.27
|
|
Diluted
|
$
|
0.86
|
|
|
$
|
0.58
|
|
|
$
|
1.93
|
|
|
$
|
1.24
|
|
|
|
|
|
|
|
|
|
Weighted-average
common shares outstanding:
|
|
|
|
|
|
|
|
Basic
|
210.5
|
|
|
212.2
|
|
|
210.8
|
|
|
212.6
|
|
Diluted
|
215.7
|
|
|
217.3
|
|
|
216.1
|
|
|
217.6
|
|
|
|
|
|
|
|
|
|
Operating
statistics
|
|
|
|
|
|
|
|
As a percentage of
net sales:
|
|
|
|
|
|
|
|
Gross
profit
|
74.9
|
%
|
|
73.3
|
%
|
|
75.3
|
%
|
|
73.7
|
%
|
Selling, general, and
administrative expenses
|
29.0
|
%
|
|
30.1
|
%
|
|
27.4
|
%
|
|
30.3
|
%
|
Research and
development expenses
|
16.0
|
%
|
|
14.8
|
%
|
|
15.2
|
%
|
|
14.7
|
%
|
Income before
provision for income taxes
|
24.4
|
%
|
|
22.3
|
%
|
|
28.9
|
%
|
|
24.2
|
%
|
Net income
|
22.1
|
%
|
|
16.7
|
%
|
|
24.1
|
%
|
|
18.5
|
%
|
|
|
|
|
|
|
|
|
Effective tax
rate
|
9.5
|
%
|
|
25.1
|
%
|
|
16.6
|
%
|
|
23.5
|
%
|
|
|
|
|
Note: Numbers may not
calculate due to rounding.
|
EDWARDS
LIFESCIENCES CORPORATION
|
Unaudited Balance
Sheets
|
(in
millions)
|
|
|
June 30,
2017
|
|
December 31,
2016
|
ASSETS
|
|
|
|
|
|
|
|
Current
assets
|
|
|
|
Cash and cash
equivalents
|
$
|
508.2
|
|
|
$
|
930.1
|
|
Short-term
investments
|
623.6
|
|
|
341.0
|
|
Accounts and other
receivables, net
|
510.7
|
|
|
414.6
|
|
Inventories,
net
|
491.6
|
|
|
396.6
|
|
Prepaid
expenses
|
54.1
|
|
|
45.9
|
|
Other current
assets
|
95.2
|
|
|
111.8
|
|
Total current
assets
|
2,283.4
|
|
|
2,240.0
|
|
|
|
|
|
Long-term
investments
|
551.5
|
|
|
532.1
|
|
Property, plant, and
equipment, net
|
627.9
|
|
|
580.0
|
|
Goodwill
|
965.1
|
|
|
626.1
|
|
Other intangible
assets, net
|
408.6
|
|
|
204.8
|
|
Deferred income
taxes
|
185.2
|
|
|
203.8
|
|
Other
assets
|
116.8
|
|
|
123.2
|
|
|
|
|
|
Total
assets
|
$
|
5,138.5
|
|
|
$
|
4,510.0
|
|
|
|
|
|
LIABILITIES AND
STOCKHOLDERS' EQUITY
|
|
|
|
|
|
|
|
Current
liabilities
|
|
|
|
Accounts payable and
accrued liabilities
|
$
|
562.5
|
|
|
$
|
532.5
|
|
|
|
|
|
Long-term
debt
|
1,016.8
|
|
|
822.3
|
|
Contingent
consideration liabilities
|
198.7
|
|
|
31.6
|
|
Other long-term
liabilities
|
420.9
|
|
|
504.6
|
|
|
|
|
|
Stockholders'
equity
|
|
|
|
Common
stock
|
244.7
|
|
|
242.6
|
|
Additional paid-in
capital
|
1,267.0
|
|
|
1,167.8
|
|
Retained
earnings
|
4,331.9
|
|
|
3,906.3
|
|
Accumulated other
comprehensive loss
|
(157.8)
|
|
|
(198.4)
|
|
Treasury stock, at
cost
|
(2,746.2)
|
|
|
(2,499.3)
|
|
Total stockholders'
equity
|
2,939.6
|
|
|
2,619.0
|
|
|
|
|
|
Total liabilities and
stockholders' equity
|
$
|
5,138.5
|
|
|
$
|
4,510.0
|
|
EDWARDS LIFESCIENCES CORPORATION
Non-GAAP Financial
Information
To supplement the consolidated financial results prepared in
accordance with Generally Accepted Accounting Principles ("GAAP"),
the Company uses non-GAAP historical financial measures.
Management makes adjustments to the GAAP measures for items (both
charges and gains) that (a) do not reflect the core operational
activities of the Company, (b) are commonly adjusted within the
Company's industry to enhance comparability of the Company's
financial results with those of its peer group, or (c) are
inconsistent in amount or frequency between periods (albeit such
items are monitored and controlled with equal diligence relative to
core operations). The Company uses the term "underlying" when
referring to non-GAAP sales information, which excludes foreign
exchange fluctuations, adjustments for discontinued and acquired
products, sales return reserves associated with transcatheter heart
valve therapy ("THVT") product upgrades, and the impact of THVT
stocking sales and consumption in Germany. The Company uses the
term "adjusted" to also exclude intellectual property litigation
expenses, amortization of intellectual property, fair value
adjustments to contingent consideration liabilities arising from
acquisitions, gains and losses from significant investments,
impairments, litigation, the impact of THVT stocking sales and
consumption in Germany, and business development
transactions. Fluctuations in exchange rates impact the
comparative results and sales growth rates of the Company's
underlying business. Management believes that excluding the impact
of foreign exchange rate fluctuations from its sales growth
provides investors a more useful comparison to historical financial
results. The impact of foreign exchange rate fluctuations has been
detailed in the "Reconciliation of Sales by Product Group and
Region."
Guidance for sales and sales growth rates is provided on an
"underlying basis," and projections for diluted earnings per share,
net income and growth, gross profit margin, taxes, and free cash
flow are also provided on a non-GAAP basis as adjusted for the
items identified below due to the inherent difficulty in
forecasting such items. The Company is not able to provide a
reconciliation of the non-GAAP guidance to comparable GAAP measures
due to the unknown effect, timing, and potential significance of
special charges or gains, and management's inability to forecast
charges associated with future transactions and initiatives.
Management considers free cash flow to be a liquidity measure
which provides useful information to management and investors about
the amount of cash generated by business operations, after
deducting payments for capital expenditures, which can then be used
for strategic opportunities or other business purposes including,
among others, investing in the Company's business, making strategic
acquisitions, strengthening the balance sheet, and repurchasing
stock.
Management uses non-GAAP financial measures internally for
strategic decision making, forecasting future results, and
evaluating current performance. These non-GAAP financial
measures are used in addition to and in conjunction with results
presented in accordance with GAAP and reflect an additional way of
viewing aspects of the Company's operations by investors that, when
viewed with its GAAP results, provide a more complete understanding
of factors and trends affecting the Company's business and
facilitate comparability to historical periods.
Non-GAAP financial measures are not prepared in accordance with
GAAP; therefore, the information is not necessarily comparable to
other companies and should be considered as a supplement to, and
not as a substitute for, or superior to, the corresponding measures
calculated in accordance with GAAP. A reconciliation of
non-GAAP historical financial measures to the most comparable GAAP
measure is provided in the tables below.
The items described below are adjustments to the GAAP
financial results in the reconciliations that follow:
THVT Germany Stocking Sales - In the first quarter of
2017, the Company recorded $61.8
million in net stocking sales ($48.0
million, net of related costs) to customers in Germany, as these customers elected to
purchase additional inventory in anticipation of a potential supply
interruption resulting from recent intellectual property
litigation. In the second quarter of 2017, these customers
consumed on a net basis $22.5 million
of their stocking inventory ($17.9
million, net of related costs).
THVT Sales Return Reserve and Related Costs - In the
first quarter of 2016, the Company recorded a $1.7 million reversal of its sales return reserve
($1.5 million, net of related costs)
upon delivery of the next-generation THVT products in the United States. In addition, in the
first quarter of 2016, the Company recorded inventory reserves of
$1.6 million related to estimated
excess THVT inventory expected upon introduction of next-generation
THVT products in Japan.
Intellectual Property Litigation Expenses - The Company
incurred intellectual property litigation expenses of $10.2 million and $12.2
million in the first quarter of 2017 and 2016, respectively,
and $7.7 million and $9.1 million in the second quarter of 2017 and
2016, respectively.
Amortization of Intellectual Property - The Company
recorded amortization expense of $2.1
million and $1.7 million in
the first quarter of 2017 and 2016, respectively, and $2.0 million and $1.9
million in the second quarter of 2017 and 2016,
respectively, related to intellectual property.
Change in Fair Value of Contingent Consideration
Liabilities - The Company recorded expenses of $1.1 million and $0.6
million in the first quarter of 2017 and 2016, respectively,
and $3.1 million and $0.4 million in the second quarter of 2017 and
2016, respectively, related to changes in the fair value of its
contingent consideration liabilities arising from acquisitions.
Impairment of Long-lived Assets - The Company recorded a
$31.2 million charge in the second
quarter of 2017 related to the other-than-temporary impairment of
one of its cost method investments and an associated long-term
asset related to the Company's option to acquire this investee.
Purchased In-process Research and Development - The
Company recorded a $34.5 million
charge in the second quarter of 2016 related to the acquisition of
technology for use in its transcatheter heart valve programs.
EDWARDS
LIFESCIENCES CORPORATION
|
Unaudited
Reconciliation of GAAP to Non-GAAP Financial
Information
|
(in millions,
except per share data)
|
|
RECONCILIATION OF
GAAP TO ADJUSTED NET INCOME
|
|
|
|
Three Months
Ended
June 30,
|
|
Six Months
Ended
June 30,
|
|
|
2017
|
|
2016
|
|
2017
|
|
2016
|
GAAP Net
Income
|
|
$
|
186.1
|
|
|
$
|
126.6
|
|
|
$
|
416.3
|
|
|
$
|
269.6
|
|
Growth Rate
%
|
|
47.0
|
%
|
|
|
|
54.4
|
%
|
|
|
|
|
|
|
|
|
|
|
|
Non-GAAP adjustments:
(A)
|
|
|
|
|
|
|
|
|
THVT Germany stocking
sales
|
|
17.9
|
|
|
—
|
|
|
(30.1)
|
|
|
—
|
|
THVT sales return
reserve and related costs
|
|
—
|
|
|
—
|
|
|
—
|
|
|
0.1
|
|
Intellectual property
litigation expenses
|
|
7.7
|
|
|
9.1
|
|
|
17.9
|
|
|
21.3
|
|
Amortization of
intellectual property
|
|
2.0
|
|
|
1.9
|
|
|
4.1
|
|
|
3.6
|
|
Change in fair value
of contingent consideration liabilities
|
|
3.1
|
|
|
0.4
|
|
|
4.2
|
|
|
1.0
|
|
Impairment of
long-lived assets
|
|
31.2
|
|
|
—
|
|
|
31.2
|
|
|
—
|
|
Purchased in-process
research and development
|
|
—
|
|
|
34.5
|
|
|
—
|
|
|
34.5
|
|
|
|
|
|
|
|
|
|
|
Provision for income
taxes
|
|
|
|
|
|
|
|
|
Tax effect on
reconciling items (B)
|
|
(15.7)
|
|
|
(7.5)
|
|
|
(8.8)
|
|
|
(10.9)
|
|
Adjusted Net
Income
|
|
$
|
232.3
|
|
|
$
|
165.0
|
|
|
$
|
434.8
|
|
|
$
|
319.2
|
|
Growth Rate
%
|
|
40.8
|
%
|
|
|
|
36.2
|
%
|
|
|
|
RECONCILIATION OF
GAAP TO ADJUSTED DILUTED EARNINGS PER SHARE
|
|
GAAP Diluted
Earnings Per Share
|
|
$
|
0.86
|
|
|
$
|
0.58
|
|
|
$
|
1.93
|
|
|
$
|
1.24
|
|
Growth Rate
%
|
|
48.3
|
%
|
|
|
|
55.6
|
%
|
|
|
|
|
|
|
|
|
|
|
|
Non-GAAP adjustments:
(A), (C)
|
|
|
|
|
|
|
|
|
THVT Germany stocking
sales
|
|
0.06
|
|
|
—
|
|
|
(0.11)
|
|
|
—
|
|
Intellectual property
litigation expenses
|
|
0.03
|
|
|
0.03
|
|
|
0.06
|
|
|
0.07
|
|
Amortization of
intellectual property
|
|
0.01
|
|
|
0.01
|
|
|
0.01
|
|
|
0.01
|
|
Change in fair value
of contingent consideration liabilities
|
|
0.02
|
|
|
—
|
|
|
0.02
|
|
|
0.01
|
|
Impairment of
long-lived assets
|
|
0.10
|
|
|
—
|
|
|
0.10
|
|
|
—
|
|
Purchased in-process
research and development
|
|
—
|
|
|
0.14
|
|
|
—
|
|
|
0.14
|
|
Adjusted Diluted
Earnings Per Share
|
|
$
|
1.08
|
|
|
$
|
0.76
|
|
|
$
|
2.01
|
|
|
$
|
1.47
|
|
Growth Rate
%
|
|
42.1
|
%
|
|
|
|
36.7
|
%
|
|
|
|
|
|
|
|
|
Note: Numbers may not
calculate due to rounding.
|
|
|
(A)
|
See description of
non-GAAP adjustments on the "Non-GAAP Financial Information"
page.
|
|
|
(B)
|
The tax effect on
non-GAAP adjustments is calculated based upon the impact of the
relevant tax jurisdictions' statutory tax rates on the Company's
estimated annual effective tax rate, or discrete rate in the
quarter, as applicable. The tax effect on the THVT Germany
stocking sales adjustment is calculated using the global effective
tax rate.
|
|
|
(C)
|
All amounts are tax
effected, calculated based upon the impact of the relevant tax
jurisdictions' statutory tax rates on the Company's estimated
annual effective tax rate, or discrete rate in the quarter, as
applicable.
|
EDWARDS
LIFESCIENCES CORPORATION
|
Unaudited
Reconciliation of GAAP to Non-GAAP Financial
Information
|
($ in
millions)
|
|
THVT OUTSIDE THE
UNITED STATES UNDERLYING SALES GROWTH
|
|
|
|
Three Months
Ended
June 30,
|
(in millions)
|
|
2017
|
|
2016
|
GAAP THVT Outside
the United States Sales
|
|
$
|
171.2
|
|
|
$
|
172.2
|
|
Adjustment for THVT
Germany stocking sales
|
|
22.5
|
|
|
—
|
|
Foreign exchange
impact
|
|
—
|
|
|
(4.9)
|
|
THVT Outside the
United States Underlying Sales
|
|
$
|
193.7
|
|
|
$
|
167.3
|
|
Underlying Growth
Rate %
|
|
15.8
|
%
|
|
|
EDWARDS
LIFESCIENCES CORPORATION
|
Unaudited
Reconciliation of GAAP to Non-GAAP Financial
Information
|
($ in
millions)
|
|
RECONCILIATION OF
SALES BY PRODUCT GROUP AND REGION
|
|
|
|
|
|
|
|
|
|
|
|
2017 Adjusted
|
|
2016 Adjusted
|
|
|
Sales by Product Group (QTD)
|
|
2Q
2017
|
|
2Q
2016
|
|
Change
|
|
GAAP Growth Rate*
|
|
Germany
Stocking
|
|
2Q 2017
Underlying
Sales
|
|
Sales Return Reserve
|
|
FX Impact
|
|
2Q 2016
Underlying
Sales
|
|
Underlying Growth Rate *
|
Transcatheter
Heart Valve Therapy
|
|
$
|
487.5
|
|
|
$
|
418.6
|
|
|
$
|
68.9
|
|
|
16.5
|
%
|
|
$
|
22.5
|
|
|
$
|
510.0
|
|
|
$
|
—
|
|
|
$
|
(4.9)
|
|
|
$
|
413.7
|
|
|
23.3
|
%
|
Surgical Heart
Valve Therapy
|
|
207.1
|
|
|
198.7
|
|
|
8.4
|
|
|
4.2
|
%
|
|
—
|
|
|
207.1
|
|
|
—
|
|
|
(2.8)
|
|
|
195.9
|
|
|
5.7
|
%
|
Critical
Care
|
|
147.2
|
|
|
142.0
|
|
|
5.2
|
|
|
3.7
|
%
|
|
—
|
|
|
147.2
|
|
|
—
|
|
|
(2.0)
|
|
|
140.0
|
|
|
5.1
|
%
|
Total
|
|
$
|
841.8
|
|
|
$
|
759.3
|
|
|
$
|
82.5
|
|
|
10.9
|
%
|
|
$
|
22.5
|
|
|
$
|
864.3
|
|
|
$
|
—
|
|
|
$
|
(9.7)
|
|
|
$
|
749.6
|
|
|
15.3
|
%
|
|
|
|
|
|
|
|
|
|
|
|
2017 Adjusted
|
|
2016 Adjusted
|
|
|
Sales by Product Group (YTD)
|
|
YTD
2Q 2017
|
|
YTD
2Q 2016
|
|
Change
|
|
GAAP Growth Rate*
|
|
Germany
Stocking
|
|
YTD 2Q
2017
Underlying
Sales
|
|
Sales Return Reserve
|
|
FX Impact
|
|
YTD 2Q
2016
Underlying
Sales
|
|
Underlying Growth Rate *
|
Transcatheter
Heart Valve Therapy
|
|
$
|
1,026.7
|
|
|
$
|
786.4
|
|
|
$
|
240.3
|
|
|
30.6
|
%
|
|
$
|
(39.3)
|
|
|
$
|
987.4
|
|
|
$
|
(1.7)
|
|
|
$
|
(8.9)
|
|
|
$
|
775.8
|
|
|
27.3
|
%
|
Surgical Heart
Valve Therapy
|
|
406.6
|
|
|
394.6
|
|
|
12.0
|
|
|
3.0
|
%
|
|
—
|
|
|
406.6
|
|
|
—
|
|
|
(4.2)
|
|
|
390.4
|
|
|
4.1
|
%
|
Critical
Care
|
|
292.0
|
|
|
275.6
|
|
|
16.4
|
|
|
6.0
|
%
|
|
—
|
|
|
292.0
|
|
|
—
|
|
|
(2.2)
|
|
|
273.4
|
|
|
6.8
|
%
|
Total
|
|
$
|
1,725.3
|
|
|
$
|
1,456.6
|
|
|
$
|
268.7
|
|
|
18.4
|
%
|
|
$
|
(39.3)
|
|
|
$
|
1,686.0
|
|
|
$
|
(1.7)
|
|
|
$
|
(15.3)
|
|
|
$
|
1,439.6
|
|
|
17.1
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2017 Adjusted
|
|
2016 Adjusted
|
|
|
Sales by Region (QTD)
|
|
2Q
2017
|
|
2Q
2016
|
|
Change
|
|
GAAP Growth
Rate*
|
|
Germany
Stocking
|
|
2Q 2017
Underlying
Sales
|
|
Sales Return
Reserve
|
|
FX Impact
|
|
2Q 2016
Underlying
Sales
|
|
Underlying Growth Rate *
|
United
States
|
|
$
|
478.9
|
|
|
$
|
401.5
|
|
|
$
|
77.4
|
|
|
19.3
|
%
|
|
$
|
—
|
|
|
$
|
478.9
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
401.5
|
|
|
19.3
|
%
|
Europe
|
|
183.7
|
|
|
203.6
|
|
|
(19.9)
|
|
|
(9.7)
|
%
|
|
22.5
|
|
|
206.2
|
|
|
—
|
|
|
(6.5)
|
|
|
197.1
|
|
|
4.6
|
%
|
Japan
|
|
90.5
|
|
|
79.9
|
|
|
10.6
|
|
|
13.2
|
%
|
|
—
|
|
|
90.5
|
|
|
—
|
|
|
(2.1)
|
|
|
77.8
|
|
|
16.3
|
%
|
Rest of
World
|
|
88.7
|
|
|
74.3
|
|
|
14.4
|
|
|
19.6
|
%
|
|
—
|
|
|
88.7
|
|
|
—
|
|
|
(1.1)
|
|
|
73.2
|
|
|
21.2
|
%
|
International
|
|
362.9
|
|
|
357.8
|
|
|
5.1
|
|
|
1.5
|
%
|
|
22.5
|
|
|
385.4
|
|
|
—
|
|
|
(9.7)
|
|
|
348.1
|
|
|
10.7
|
%
|
Total
|
|
$
|
841.8
|
|
|
$
|
759.3
|
|
|
$
|
82.5
|
|
|
10.9
|
%
|
|
$
|
22.5
|
|
|
$
|
864.3
|
|
|
$
|
—
|
|
|
$
|
(9.7)
|
|
|
$
|
749.6
|
|
|
15.3
|
%
|
|
|
|
|
|
|
|
|
|
|
|
2017 Adjusted
|
|
2016 Adjusted
|
|
|
Sales by Region (YTD)
|
|
YTD
2Q 2017
|
|
YTD
2Q 2016
|
|
Change
|
|
GAAP Growth
Rate*
|
|
Germany
Stocking
|
|
YTD 2Q
2017
Underlying
Sales
|
|
Sales Return
Reserve
|
|
FX Impact
|
|
YTD 2Q
2016
Underlying
Sales
|
|
Underlying Growth Rate *
|
United
States
|
|
$
|
943.5
|
|
|
$
|
777.1
|
|
|
$
|
166.4
|
|
|
21.4
|
%
|
|
$
|
—
|
|
|
$
|
943.5
|
|
|
$
|
(1.7)
|
|
|
$
|
—
|
|
|
$
|
775.4
|
|
|
21.7
|
%
|
Europe
|
|
444.7
|
|
|
392.1
|
|
|
52.6
|
|
|
13.4
|
%
|
|
(39.3)
|
|
|
405.4
|
|
|
—
|
|
|
(14.7)
|
|
|
377.4
|
|
|
7.4
|
%
|
Japan
|
|
169.8
|
|
|
146.5
|
|
|
23.3
|
|
|
15.9
|
%
|
|
—
|
|
|
169.8
|
|
|
—
|
|
|
(1.3)
|
|
|
145.2
|
|
|
16.9
|
%
|
Rest of
World
|
|
167.3
|
|
|
140.9
|
|
|
26.4
|
|
|
18.7
|
%
|
|
—
|
|
|
167.3
|
|
|
—
|
|
|
0.7
|
|
|
141.6
|
|
|
18.1
|
%
|
International
|
|
781.8
|
|
|
679.5
|
|
|
102.3
|
|
|
15.1
|
%
|
|
(39.3)
|
|
|
742.5
|
|
|
—
|
|
|
(15.3)
|
|
|
664.2
|
|
|
11.8
|
%
|
Total
|
|
$
|
1,725.3
|
|
|
$
|
1,456.6
|
|
|
$
|
268.7
|
|
|
18.4
|
%
|
|
$
|
(39.3)
|
|
|
$
|
1,686.0
|
|
|
$
|
(1.7)
|
|
|
$
|
(15.3)
|
|
|
$
|
1,439.6
|
|
|
17.1
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
* Numbers may not
calculate due to rounding.
|
View original content with
multimedia:http://www.prnewswire.com/news-releases/edwards-lifesciences-reports-second-quarter-results-300494734.html
SOURCE Edwards Lifesciences Corporation